Albert David Ltd

Albert David Ltd

₹ 1,125 -0.28%
19 Apr - close price
About

Albert David Ltd is engaged in manufacturing and trading of Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms and Bulk Drugs by way of domestic sale or export.[1]

Key Points

Product Offerings
The company offers a wide range of formulations under its various brands in the domestic market[1]
Its placental-based formulation, Placentrex, is the only human placenta-based product in India developed through indigenous research. It has emerged as the market leader in this segment and has a process patent over Placentrex. The product portfolio is largely restricted to acute therapeutic segments such as antibacterials, anti-infectives, and placental extracts. [2]

  • Market Cap 643 Cr.
  • Current Price 1,125
  • High / Low 1,608 / 554
  • Stock P/E 9.70
  • Book Value 614
  • Dividend Yield 0.80 %
  • ROCE 17.0 %
  • ROE 12.2 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 35.0% CAGR over last 5 years

Cons

  • The company has delivered a poor sales growth of 3.64% over past five years.
  • Company has a low return on equity of 11.5% over last 3 years.
  • Earnings include an other income of Rs.47.1 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
65 57 81 86 72 74 93 92 75 81 92 93 88
60 50 71 73 64 64 81 78 66 72 79 77 80
Operating Profit 6 7 10 13 7 10 12 14 8 10 13 16 8
OPM % 9% 12% 13% 15% 10% 13% 13% 15% 11% 12% 14% 17% 9%
5 4 5 5 6 -1 -6 14 7 0 18 12 17
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 2 2 2 2 2 2 2 2 2 2 2 1 2
Profit before tax 8 9 13 16 11 7 4 26 14 7 29 27 23
Tax % 27% 18% 21% 23% 27% 38% 60% 21% 22% 48% 20% 24% 20%
6 7 10 13 8 4 2 20 11 4 23 20 19
EPS in Rs 10.72 12.77 18.31 22.20 13.96 7.31 3.08 35.29 18.49 6.54 41.16 35.57 32.80
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
228 261 287 317 318 293 285 316 320 246 313 341 355
204 236 254 281 286 266 267 286 289 227 272 297 308
Operating Profit 24 26 33 37 31 27 18 30 30 19 41 44 47
OPM % 11% 10% 11% 12% 10% 9% 6% 10% 10% 8% 13% 13% 13%
1 2 1 2 43 8 9 15 7 17 16 15 47
Interest 4 4 4 3 2 1 1 1 1 1 1 1 0
Depreciation 10 11 11 15 9 8 8 7 8 8 9 9 7
Profit before tax 11 13 18 20 63 26 18 38 29 27 47 51 86
Tax % 32% 36% 32% 32% 24% 39% 45% 29% 34% 19% 25% 29%
8 9 13 14 48 16 10 27 19 22 35 36 66
EPS in Rs 13.37 15.00 22.02 24.00 84.10 27.96 17.24 46.68 33.59 38.79 61.78 63.38 116.07
Dividend Payout % 34% 30% 23% 23% 7% 20% 32% 13% 21% 15% 15% 14%
Compounded Sales Growth
10 Years: 3%
5 Years: 4%
3 Years: 2%
TTM: 6%
Compounded Profit Growth
10 Years: 16%
5 Years: 35%
3 Years: 24%
TTM: 81%
Stock Price CAGR
10 Years: 25%
5 Years: 23%
3 Years: 34%
1 Year: 90%
Return on Equity
10 Years: 11%
5 Years: 11%
3 Years: 12%
Last Year: 12%

Balance Sheet

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 6 6 6 6 6 6 6 6 6 6 6 6 6
Reserves 70 75 85 87 131 177 180 205 217 239 274 306 345
40 38 42 30 20 30 28 0 2 2 6 5 1
88 64 66 71 67 71 76 84 95 95 116 106 103
Total Liabilities 203 183 198 193 224 285 290 295 320 341 401 423 455
69 72 67 49 44 87 83 77 91 84 88 80 79
CWIP 6 1 3 5 5 9 5 5 2 1 1 3 9
Investments 0 0 16 16 48 59 68 113 122 138 183 193 225
127 110 111 122 127 130 134 99 106 119 130 148 142
Total Assets 203 183 198 193 224 285 290 295 320 341 401 423 455

Cash Flows

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
11 20 21 28 68 20 30 32 30 37 40 11
-12 -9 -24 -9 -38 -36 -11 -19 -20 -37 -40 -5
-11 -8 -2 -18 -18 7 -5 -17 -10 -2 -2 -6
Net Cash Flow -12 3 -5 1 12 -10 15 -4 0 -2 -1 -1

Ratios

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 48 52 54 47 41 41 35 25 34 29 29 32
Inventory Days 189 165 191 176 187 217 173 151 148 151 124 150
Days Payable 146 110 135 103 102 117 127 102 132 104 96 95
Cash Conversion Cycle 90 107 111 120 126 141 81 74 50 76 57 87
Working Capital Days 55 61 57 52 48 61 45 22 18 -8 -29 18
ROCE % 16% 14% 18% 18% 17% 15% 7% 18% 14% 12% 17% 17%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
61.25% 61.35% 61.64% 61.96% 61.99% 61.99% 61.99% 62.04% 62.04% 62.04% 62.04% 62.13%
0.00% 0.50% 0.71% 0.75% 0.64% 0.61% 0.57% 0.57% 0.65% 0.57% 0.70% 0.98%
3.53% 3.18% 3.18% 3.18% 3.17% 2.97% 2.84% 2.80% 2.30% 1.90% 1.67% 1.67%
35.22% 34.97% 34.47% 34.11% 34.19% 34.43% 34.60% 34.59% 35.01% 35.49% 35.60% 35.23%
No. of Shareholders 12,29211,99210,77910,64510,70810,38110,0109,7869,8289,90710,04111,266

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents